Latest News

FDA grants priority review to Belite Bio's tinlarebant NDA for Stargardt disease type 1, setting a February 2027 PDUFA date for a potential first STGD1 therapy.

Sight Sciences' newest MIGS device gains FDA clearance for single-pass canaloplasty and trabeculotomy in open-angle glaucoma.

The trial is evaluating the company’s orally administered synthetic cannabinoid, ART27.13

Gene therapies, Tie2 agonism, and new delivery platforms are advancing through phase 3 trials in wet and dry AMD, testing mechanisms distinct from anti-VEGF and complement inhibition.

In this Q&A from EDES 2026 in Milan, Piotr A. Woźniak, MD, PhD, discusses his real-world evidence study on a dry eye lubricating drop, including its effects on tear film stability.

Bakall on 3-year REMAIN data for MCO-010 in retinitis pigmentosa: durable 3-line acuity gains, why genotype did not matter, and which patients responded best.

Harrow to acquire Tyrvaya, the only FDA-approved nasal spray for dry eye disease, from Viatris for up to $100 million, complementing its cyclosporine product Vevye.

An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.

Private practice fellowships sharpen cataract and refractive skills with high volume, new tech, and hands-on practice management mentorship.

This article discusses the current treatments being investigated during the first half of 2026.

Barakat, MD, FASRS, on recognizing neovascular conversion in macular telangiectasia type 2, distinguishing it from neovascular AMD on imaging, and treating it without a robust evidence base.

Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.

In part 2 of a 2-part article, Arun C. Gulani, MD, walks through the 4 patient types of the Gulani classification of refractive lens exchange, from primary vision enhancement to staged vision engineering, and explains why outcomes depend on treating the eye as a complete optical system rather than on the implant alone.